Neurotrophic factor changes are essential for predict electroconvulsive therapy outcome in schizophrenia

Area of Science:

• Neuroscience
• Psychiatry
• Biochemistry

Background:

• Brain-derived neurotrophic factor (BDNF) is implicated in schizophrenia treatment.
• The mediating role of BDNF in electroconvulsive therapy (ECT) and antipsychotic (AP) treatment efficacy remains unclear.

Purpose of the Study:

• To investigate whether baseline BDNF levels mediate the efficacy of ECT-AP treatment in schizophrenia.
• To determine the predictive value of BDNF levels for treatment response.

Main Methods:

• 160 schizophrenia patients were studied, divided into AP monotherapy and ECT+AP groups.
• BDNF concentration was measured using enzyme-linked immunosorbent assay (ELISA).
• Log-linear analyses assessed relationships between demographics, BDNF, clinical features, and response status.

Main Results:

• Baseline BDNF levels and BDNF level increment were significant predictors of clinical outcome.
• Higher baseline BDNF levels (OR=3.358, P=0.000) and greater BDNF increment (OR=3.243, P=0.000) were associated with good treatment response.
• BDNF levels appear to mediate the efficacy of combined ECT and AP treatment.

Conclusions:

• Baseline BDNF levels and their changes during treatment are crucial indicators of treatment success in schizophrenia.
• BDNF may serve as a biomarker for predicting treatment response to ECT and APs.
• Further research into BDNF's role can optimize schizophrenia therapeutic strategies.